NSCLC: Selecting Therapy Based on PD-L1 Status and Staging
It was with the trial CheckMate 816 and the chemo‑plus‑checkpoint inhibitor therapy that the subset based on PD‑L1 expression all patients seemed to benefit, with more benefit at higher PD‑L1 levels.
A brief review of how treatment may be selected for a patient with NSCLC based on their PD‑L1 expression and disease staging.
Understanding how PD‑L1 status influences therapeutic benefit in early‑stage non‑small cell lung cancer informs decisions between neoadjuvant chemo‑immunotherapy versus adjuvant therapy, potentially improving outcomes.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT